Immunology
| 4 min read
The Nurix and Roche partnership on bexobrutideg is the latest sign that targeted protein degradation is moving well beyond oncology.
| 3 min read
The newly approved drug vastly reduced the amount of antibodies that would usually lead to organ rejection in a patient who had no chance of receiving a matched transplant.
| 4 min read
Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops.
| 3 min read
Researchers find that infant airway tissue actively shapes the immune response to RSV, suggesting future therapies should target both the virus and inflammation.
| 5 min read
Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence.
| 3 min read
Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity.
| 4 min read
Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need.
| 3 min read
Trained on more than 30,000 tumor genomes, MutationProjector offers drug developers a broader framework for connecting cancer genetics to therapy outcomes.
| 5 min read
A $15 million international study is investigating patients in long-term remission to understand whether lupus can truly switch off — and what that reveals about the immune system.
| 5 min read
Endometriosis is still largely managed with pain relief, hormones, and surgery, but a new precision peptide therapy seeks to directly target the underlying lesion biology.
| 2 min read
The collaboration combines VRG’s AI platform with AOP Health’s expertise in rare diseases and immunology to develop a highly selective therapeutic targeting Kv1.3-mediated immune dysfunction.
| 5 min read
Real-world data and late-stage trial results at DDW 2026 highlight persistent gaps in long-term IBD control despite therapeutic advances.
